News

• HOOKIPA Announces First Patient Dosed in Phase 1/2 Clinical Trial for HB-202/HB-201 Alternating Vector Therapy to Treat Human Papillomavirus 16-Positive Cancers
  12:30 - GlobeNewswire
•  
• Gilead's Q3 revenue at $6.6B, up 17% YoY
  10/28/2020 / 21:04 - TeleTrader
•  
• WHO questions FDA's approval of remdesivir
  10/23/2020 / 18:16 - TeleTrader
•  
• US opens higher as investors focus on stimulus talks
  10/23/2020 / 15:31 - TeleTrader
•  
• Gilead soars as remdesivir receives FDA approval
  10/23/2020 / 14:17 - TeleTrader
•  
• US higher in premarket on stimulus, vaccine hopes
  10/23/2020 / 10:30 - TeleTrader
•  
• Gilead's drug remdesivir receives FDA approval
  10/22/2020 / 22:03 - TeleTrader
•  
• National AIDS Memorial to Honor Anthony S. Fauci, M.D. and David D. Ho, M.D., on World AIDS Day for their Leadership on the Frontlines of the AIDS and Covid-19 Pandemics
  10/22/2020 / 19:46 - GlobeNewswire
•  
• Gene Therapy Company AavantiBio Launches with $107 Million Series A Financing from Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management and Sarepta Therapeutics
  10/22/2020 / 13:30 - GlobeNewswire
•  
• HOOKIPA Appoints Prof. Jean-Charles Soria, Director General of the Gustave Roussy Cancer Center in Paris, to its Board of Directors
  10/19/2020 / 14:00 - GlobeNewswire
•  
• Gilead questions quality of WHO remdesivir study
  10/16/2020 / 04:26 - TeleTrader
•  
• Remdesivir has no major effect on COVID mortality - report
  10/15/2020 / 21:16 - TeleTrader
•  
• PHASE 2B/3 TRIAL SHOWS EFFICACY OF FILGOTINIB FOR THE INDUCTION AND MAINTENANCE OF REMISSION IN MODERATELY AND SEVERELY ACTIVE ULCERATIVE COLITIS
  10/12/2020 / 15:15 - GlobeNewswire
•  
• National AIDS Memorial to Launch 50-State AIDS Memorial Quilt Virtual Exhibition in Conjunction with World AIDS Day
  10/09/2020 / 20:48 - GlobeNewswire
•  
• Gilead to have enough global supply of remdesivir by November
  10/09/2020 / 14:21 - TeleTrader